Roivant unveils mosliciguat, inhaled sGC activator for PH-ILD; Phase 1b shows PVR reduction up to 38%

Roivant Sciences Ltd.

Phase 1b ATMOS in 38 PH patients: single dose of mosliciguat produced mean-max PVR reduction up to ~38%, exceeding ≥20% threshold.
Mosliciguat is potential first-in-class, inhaled once-daily sGC activator with targeted lung delivery via dry powder inhaler.
Global Phase 2 PHocus study in ~120 PH-ILD patients imminent; PH-ILD prevalence ~200,000 in US/Europe with few treatments.
Roivant in-licensed from Bayer for ~$14M upfront, up to $280M milestones + tiered high-single digit royalties.
Favorable safety in 170 participants; 40-hour half-life enables once-daily dosing; differentiated from existing therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.